pembrolizumab
medsir,merck
['keynote-b10', 'key,note,42', 'pembro', 'medsir']
presentation by #marcindzienis of keynote-b10 trial shows clinical activity (orr 42.7%) and manageable toxicity of pembro + carbo + pacli as first-line therapy in pts with r/m hnscc, suggesting this 5-fu-free chemo as an alternative to current soc #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM